Mehra, N., Clarke, N. W., Armstrong, A. J., Oya, M., Shore, N. D., Procopio, G., … Saad, F. (2023). 1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial. In Annals of Oncology (Vol. 34, pp. S975–S976). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2753

Mehra, N., N. W. Clarke, A. J. Armstrong, M. Oya, N. D. Shore, G. Procopio, J. D. C. Guedes, et al. “1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial.” In Annals of Oncology, 34:S975–76. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2753.

Mehra N, Clarke NW, Armstrong AJ, Oya M, Shore ND, Procopio G, et al. 1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial. In: Annals of Oncology. Elsevier BV; 2023. p. S975–6.

Mehra, N., et al. “1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S975–76. Crossref, doi:10.1016/j.annonc.2023.09.2753.

Mehra N, Clarke NW, Armstrong AJ, Oya M, Shore ND, Procopio G, Guedes JDC, Arslan C, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Choi YD, Castellano D, Urun Y, Hosius C, Desai C, Degboe A, Saad F. 1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial. Annals of Oncology. Elsevier BV; 2023. p. S975–S976.